See good boost in revenues in FY13: Natco Pharma

3964 Investors following Natco Pharma. Share this News with them.

0

Like this story, share it with millions of investors on M3

See good boost in revenues in FY13: Natco Pharma

In an interview to CNBC-TV18, Bhaskar Narayana, chief financial officer of Natco Pharma says, FY13 should see atleast one abbreviated new drug application (ANDA) coming through. “FY13 would be a very exciting year for the company because it should result in good boost to the revenues,” he adds.

Post your opinion here

 

0

Tweet

Share on Tumblr

ALSO READ See latest News about Natco Pharma See previous management interviews See what other Experts & Brokerages are saying about Natco Pharma Natco Pharma BSE | NSE 29/05/12 Are Mutual Funds betting on Natco Pharma?

In an interview to CNBC-TV18, Bhaskar Narayana, chief financial officer of Natco Pharma says, FY13 should see atleast one abbreviated new drug application (ANDA) coming through. "FY13 would be a very exciting year for the company because it should result in good boost to the revenues," he adds.

Below is the edited transcript of his interview with CNBC-TV18's Reema Tendulkar and Ekta Batra. Also watch the accompanying video.

Q: The company will be making a multiple sclerosis drug for Mylan. How significant is this? What kind of an opportunity is it in terms of revenues?

A: We have filed an abbreviated new drug application for permission to market Galtiramer Acetate in the US. Consequently, we have tied up with Mylan Inc. We are in the final phase of setting up dedicated manufacturing blocks for manufacture of this product. So, the matter is presently sub-judice it's before the court in US. Therefore, we would not wish to comment anything on that as of now in terms of when and what and how much.

Q: When you would start producing this multiple sclerosis drug for Mylan? Would you be the only company which is in tie up with Mylan for this?

A: The agreement between us and Mylan is an exclusive one. Therefore, we are the only one that has tied up with Mylan. The facility is ready for production. But since the matter is pending before the court, we cannot say with certainty as to when we can start the production.

Q: Recently, Dilip Sanghvi in a personal capacity acquired stake in the company. Any further plans from Mr. Sanghvi to increase his stake in the company?

A: As you rightly said the stake was acquired in his personal capacity. That shows that he has got lot of belief in the business model of the company and I think it rests there. We don't have any further information or discussions with him.

Q: How is your agreement with DRL progressing?

A: It's progressing alright. It is a basket of products. So, it's obviously going to take time but its on the right path.

Q: The company was also expected to have an first-to-file (FTF) on Tamiflu generic.

A: We have filed an abbreviated new drug application (ANDA). We have got the first-to-file status. The ANDA has to be approved. It is in the process so it will take some more time.

Q: What sort of FTF opportunities the company has at this point in time and anything which we could expect in the near future from the company? Any more filings that you have done?

A: Of the total 21 odd filings that we have done, about five filings are Para IV challenges. Out of the five, about four we have first-to-file status. These are for Lenalidomide and Tamiflu and Lanthanum Carbonate and one more product. These are all multi billion products commanding more than 2 billion in market share, atleast some of them. Process is on. These provide a good upside to the company as when they result into approved authorisations.

Q: Which ones have you already decisively heard from the US FDA on in terms of you having a FTF on it?

A: We have this FTF for Lenalidomide, Tami flu, Lapatinib. We have a shared first-to-file for Lanthanum carbonate.

Q: What's the revenue growth that we could expect from Natco Pharma in FY13?

A: FY13 should see atleast one abbreviated new drug application (ANDA) coming through. FY13, personally would be a very exciting year for the company because it should result in good boost to the revenues depending on which product gets approved and how it is planned to be marketed and launched. FY13 should be an exciting year.